DOI: 10.21276/ajptr
Sun, 21 Jul 2019

Alpha Amylase As A Biological Scaffold For Design of Novel Antidiabetic Drugs- A Review

Nikhila Jose1*, K Krishnakumar1, G Elias1

1.Dept. of Pharmaceutical Chemistry, St James College of Pharmaceutical Sciences, Chalakudy, Kerala


Diabetes Mellitus is a metabolic disorder characterized by high blood glucose level caused by deficiency of insulin secretion or insulin action. Postprandial blood glucose level in patients with type II diabetes may be controlled by inhibition of alpha amylase, which is one of the carbohydrate hydrolysing enzymes. Alpha amylase is an enzyme which breaks down starch to maltose by hydrolysing alpha bonds of large, alpha-linked polysaccharides, such as starch and glycogen. Alpha amylase inhibitors may be useful as adjuvant drugs in type II diabetes. The objective of this review is to gather information regarding the identification and evaluation of alpha amylase inhibitors from natural and synthetic sources.

Keywords: Alpha amylase, antidiabetic.

[PDF]   Viewed: 721   Downloaded: 62
  • Call for paper

    American Journal of PharmTech Research (AJPTR) is a peer-reviewed, bimonthly official international journal allowing access to abstracts and full-text.



  • Email & SMS Alerts

    Email/SMS alert system is one of the key features and gives update information about the submitted manuscript.


  • Article Statastics

    American Journal of PharmTech Research (AJPTR) provides unique facility for authors to know popularity of articles on basis of numbers of PDF download and views. It will display in tabulated format.

  • Online Submission

    American Journal of PharmTech Research (AJPTR) is one of the International open access journal devoted to various disciplines in science and technology.


web counter
web counter